NEWS | FINANCIAL DOCUMENTS | CORPORATE GOVERNANCE
View all of the Pharming SEC filings through EDGAR on the SEC website.
2024
April 25, 2024 6-K, "Pharming convertible bond launch, pricing and repurchase results"
April 24, 2024 6-K, "Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards"
April 8, 2024 6-K, "Pharming announces completion of enrollment in pediatric clinical trial of leniolisib"
April 4, 2024 6-K, "Pharming Group announces the filing of its 2023 Annual Report and Form 20-F and convenes the Annual General Meeting of Shareholders 2024"
April 4, 2024 20-F, "2023 Annual report on Form 20-F submitted to the U.S. Securities and Exchange Commission"
March 14, 2024 6-K, "Pharming Group reports fourth quarter and full year 2023 financial results"
January 8, 2024 6-K, "Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update"
2023
December 13, 2023 6-K, "Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)"
November 10, 2023 6-K, "Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval"
October 26, 2023 6-K, "Pharming Group reports third quarter 2023 financial results"
September 25, 2023 6-K, "Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders"
August 14, 2023 6-K, "Pharming Group to convene Extraordinary General Meeting of Shareholders"
August 9, 2023 6-K, "Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan"
August 3, 2023 6-K, "Pharming Group reports second quarter and first half 2023 financial results"
July 18, 2023 6-K, "Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board"
June 1, 2023 6-K, "Pharming Group announces sale of priority review voucher"
May 17, 2023 6-K, "Pharming Group reports on results of the 2023 Annual General Meeting of Shareholders"
May 11, 2023 6-K, "Pharming Group reports financial results for the first quarter of 2023"
April 11, 2023 6-K, "Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S."
April 5, 2023 20-F, "2022 Annual report on Form 20-F submitted to the U.S. Securities and Exchange Commission"
April 5, 2023 6-K, "Pharming Group announces the filing of its 2022 Annual Report and Form 20-F and covenes the Annual General Meeting of Shareholders 2023"
March 24, 2023 6-K, "Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS"
March 16, 2023 6-K, "Pharming Group reports financial results for full year 2022"
March 13, 2023 6-K, "Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank in light of US Government announcement and its cash on depost at Silicon Valley Bank Limited in light of UK Government announcement"
March 12, 2023 6-K, "Pharming Group issues statement regarding the events surrounding Silicon Valley Bank"
February 21, 2023 6-K, "Pharming announces first patient enrolled in pediatric clinical trial of leniolisib"
February 16, 2023 6-K, "Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe"
2022
-
October 27, 2022 6-K, "Pharming Group reports earnings for the first nine months of 2022"
-
August 4, 2022 6-K, "Pharming Group reports financial results for the first half of 2022"
-
August 1, 2022 6-K, "Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS"
-
June 2, 2022 6-K, "Pharming Group to present at Jefferies Healthcare Conference 2022"
-
May 18, 2022 6-K, "Pharming Group: all proposals Annual General Meeting of Shareholders approved"
-
May 12, 2022 6-K "Pharming Group reports financial results for the first quarter of 2022"
-
May 5, 2022 6-K "Pharming Group Notice of Q1 Results"
-
April 22, 2022 6-K "Pharming announces change in its holding in BioConnection following a substantial investment by new investor"
-
April 6, 2022 20-F "2021 Annual report on Form 20-F submitted to the U.S. Securities and Exchange Commission"
-
April 6, 2022 6-K "Pharming announces the filing of its 2021 Annual Report, with Form 20-F also filed with the U.S. Securities and Exchange Commission and convenes its 2022 AGM"
-
April 1, 2022 "Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting"
-
March 17, 2022 6-K "Pharming Group reports financial results for full year 2021"
-
March 8, 2022 6-K "Pharming Group Notice of 2021 Full Year Results"
-
February 2, 2022 6-K "Pharming announces positive results of Phase II/III pivotal clinical study of leniolisib for the treatment of activated PI3K delta syndrome"
-
January 6, 2022 6-K "Pharming receives positive EMA decision on paediatric investigation plan (PIP) for leniolisib in Europe"
-
January 4, 2022 6-K "Pharming Group and Sanofi renew strategic manufacturing partnership agreement"
2021
-
October 28, 2021 6-K "Pharming Group reports financial results for the first nine months of 2021"
-
October 22, 2021 6-K "Pharming Group Notice of 9M Results"
-
September 14, 2021 6-K "Pharming announces results from clinical trials for the treatment of COVID-19 with RUCONEST®"
-
August 5, 2021 6-K "Pharming Group reports financial results for the first half of 2021"
-
July 20, 2021 6-K "Pharming signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST® in the Middle East and North Africa"
-
July 1, 2021 6-K "Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo HSC Gene Therapy for Hereditary Angioedema"
-
June 23, 2021 6-K ''Pharming announces completion of enrolment in Phase II/III study with leniolisib for activated PI3K delta syndrome''
-
June 18, 2021 6-K ''Pharming appoints Anurag Relan as Chief Medical Officer and Robert Friesen as Chief Scientific Officer''
-
June 4, 2021 6-K ''Pharming Group N.V. announces the reimbursement of RUCONEST® in Spain''
-
June 1, 2021 6-K ''Pharming Group to present at Jefferies Virtual Healthcare Conference''
-
May 19, 2021 6-K ''Pharming Reports on Annual General Meeting of Shareholders''
-
May 13, 2021 6-K "Pharming Group reports financial results for the first quarter of 2021"
-
April 22, 2021 6-K ''Pharming announces enrollment of first patient in multicenter Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction''
-
April 7, 2021 20-F "2020 Annual report on Form 20-F submitted to the U.S. Securities and Exchange Commission"
-
April 7, 2021 6-K "Pharming Group announces the filing of its 2020 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission"
-
April 6, 2021 6-K ''Pharming Group announces the publication of its 2020 Annual Report and convenes its 2021 AGM''
-
March 23, 2021 6-K "Pharming Group announces the intention to nominate three Non-Executive Directors to the Board of Directors"
-
March 16, 2021 6-K "Pharming Group to present at 31st Annual Oppenheimer Healthcare"
-
March 11, 2021 6-K "Pharming Group to Present at BioCapital Europe 2021"
-
March 4, 2021 6-K "Pharming Group reports financial results for full year 2020"
-
March 2, 2021 6-K "Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program ‘navigateAPDS’"
2020
-
December 22, 2020 6-K: "Pharming Group announces ADSs admitted to trade on Nasdaq under the symbol “PHAR"
-
December 22, 2020 6-K: "Pharming Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs Costs for conversion of Ordinary Shares into ADS’s waived by JP Morgan Chase for initial four weeks after today"
-
December 22, 2020 F-1 Registration Statement